Publication: 4611

Publication: 4611

Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602)

DOI

Google Scholar

Citation:

Meeting Instance:: ASCO 2025
Year:: 2025
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: Yes

Parents:: None
Children:: None

Program:: CCP
Primary Committee:: Health Outcomes
Sec. Committees:: GI

Pharmas:: Exelixis
Grants:: U10CA180821, U10CA180882; U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG Oncology); U10CA180888 (SWOG);

Corr. Author:
Authors:: Amylou C. Dueck Briant Fruth Susan Geyer Tyler Zemla Sydney Pulsipher Fang-Shu Ou Jared Acoba Ardaman Shergill Edward M. Wolin Thorvardur R. Halfdanarson Bhavana Konda Nikolaos A. Trikalinos Shagufta Shaheen Namrata Vijayvergia Arvind Dasari Jonathan R. Strosberg Eileen M. O'Reilly Jeffrey A. Meyerhardt Jennifer A. Chan

Networks:: FL065, HAWAII, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NY021

Study: Alliance-A021602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: